A5071985590- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Pancreatitis Pathology and Treatment
- Cancer Cells and Metastasis
- Radiomics and Machine Learning in Medical Imaging
- Cancer Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Gallbladder and Bile Duct Disorders
- Colorectal Cancer Treatments and Studies
- Cancer Research and Treatments
- TGF-β signaling in diseases
- Renal cell carcinoma treatment
- Cell Adhesion Molecules Research
- Frailty in Older Adults
- Protease and Inhibitor Mechanisms
- Gastric Cancer Management and Outcomes
- Advanced Proteomics Techniques and Applications
- Studies on Chitinases and Chitosanases
- Cancer survivorship and care
- Colorectal Cancer Screening and Detection
- Fibroblast Growth Factor Research
- Machine Learning in Bioinformatics
- Proteoglycans and glycosaminoglycans research
Gentofte Hospital
2017-2025
Herlev Hospital
2014-2024
Copenhagen University Hospital
2015-2024
University of Copenhagen
2015-2024
German Cancer Research Center
2023
Heidelberg University
2023
CTO Andrea Alesini
2023
Academia Sinica
2023
Abstract Background Older patients with cancer are at risk of physical decline and impaired quality life during oncological treatment. Exercise training has the potential to reduce these challenges. The study aim was investigate feasibility effect a multimodal exercise intervention in older advanced (stages III/IV). Patients Methods Eighty-four adults (≥65 years) pancreatic, biliary tract, or non-small cell lung who received systemic treatment were randomized 1:1 an group control group....
To evaluate the clinical benefit of nivolumab with or without ipilimumab in combination stereotactic body radiotherapy (SBRT) patients refractory metastatic pancreatic cancer (mPC).Between November 2016 and December 2019, mPC were randomly assigned 1:1 to SBRT 15 Gy nivolumab/ipilimumab stratified by performance status (ClinicalTrials.gov identifier: NCT02866383). The primary end point was rate (CBR), defined as percentage complete partial response (PR) stable disease, according RECIST 1.1....
Background Immune-related adverse events due to immune checkpoint inhibitors (ICIs) are not always effectively treated using glucocorticoids and it may negatively affect the antitumor efficacy of ICIs. Interventional studies alternatives lacking. We examined whether interleukin-6 blockade by tocilizumab reduced ICI-induced colitis arthritis. Patients methods with solid cancer experiencing Common Terminology Criteria for Adverse Events (CTCAE v5.0) grade >1 colitis/diarrhea (n=9),...
The use of novel tools to understand tumour-fibrosis in pancreatic ductal adenocarcinoma (PDAC) and anti-fibrotic treatments are highly needed. We established a pseudo-3D vitro model including humane fibroblasts (PFs) cancer-associated (CAFs) combination with clinical collagen biomarkers, as translational drug screening tool. Furthermore, we investigated the prognostic potential serum biomarkers 810 patients PDAC. PFs CAFs were cultured Ficoll-media. Cells treated w/wo TGF-ß1 compound ALK5i....
Hyaluronan (HA) and collagen are highly expressed in pancreatic cancer (PC) stroma. HA accumulation increase tumor interstitial fluid pressure, compromising blood flow drug penetration. The aim of this biomarker study was to determine the clinical utility serum propeptide type III (PRO-C3) patients with PC. A cohort from Danish BIOPAC (NCT03311776) including histologically confirmed ductal adenocarcinoma (n = 809), ampullary carcinoma 44), distal biliary tract 31), chronic pancreatitis 15),...
Type XI collagen has been associated with tumor fibrosis and aggressiveness in patients pancreatic ductal adenocarcinoma (PDAC). The propeptide on is released into the circulation after proteolytic processing at either amino acid 253 or 511. This allows for a noninvasive biomarker approach to quantify production. We developed two ELISA-based biomarkers, targeting enzymatic cleavage sites (PRO-C11-253 PRO-C11-511). In discovery cohort including serum from PDAC (n = 39, Stages 1-4), chronic...
Circulating transforming growth factor-β (TGF-β)-specific T cells that recognize TGF-β-expressing immune regulatory have been described in patients with cancer. TGF-β-derived peptide vaccination modulates the tumor microenvironment and has shown clinical effects animal models of pancreatic cancer (PC). are especially elevated PC may prevent response to checkpoint inhibitors (ICIs). Thus, present study we investigated significance TGF-β-specific T-cell immunity treated ICI combined...
Abstract Purpose: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid tumors. Most patients are diagnosed at an advanced stage where curative surgery not option. The aim this study was to identify a panel circulating proteins that could distinguish with PDAC from non-PDAC individuals. Experimental Design: We investigated 92 known be involved in inflammation, development, and progression using Olink immuno-oncology serum samples 701 (stage I–IV), 102 nonmalignant...
In the tumor microenvironment, extracellular matrix (ECM) has been recognized as an important part of cancer development. The dominant ECM proteins are 28 types collagens, each with a unique function in tissue architecture. Type XX collagen, however, is poorly characterized, and little known about its involvement cancer. We developed ELISA quantifying type named PRO-C20, using monoclonal antibody raised against C-terminus. PRO-C20 PRO-C1, targeting N-terminal pro-peptide I was measured sera...
Precision oncology requires sensitive and specific clinical biomarkers. Carbohydrate Antigen 19-9 (CA19-9) is widely used in pancreatic ductal adenocarcinoma (PDA) but lacks sensitivity specificity. Nearly all PDAs harbor somatic KRAS mutations, nominating circulating tumor DNA (ctDNA) as an alternative disease biomarker, however, variable performance has limited its utility. We applied ultrasensitive, PCR mutation enrichment, next generation sequencing ctDNA assay a large cohort of patients...
Rare truncating BRCA2 K3326X (rs11571833) and pathogenic CHEK2 I157T (rs17879961) variants have previously been implicated in familial pancreatic ductal adenocarcinoma (PDAC), but not sporadic cases. The effect of both mutations important DNA repair genes on PDAC risk may shed light the genetic architecture this disease. Both were genotyped germline from 2,935 cases 5,626 control subjects within PANcreatic Disease ReseArch (PANDoRA) consortium. Risk estimates evaluated using multivariate...
Circulating fragments of type III collagen, measured by PRO-C3, has shown promising results as a tumor fibrosis biomarker. However, the fibrotic microenvironment consists many other collagens with diverse functions and unexplored biomarker potential. One example hereof is XXII collagen (COL22). In this study, we investigated potential COL22 measuring in serum. An ELISA, named PRO-C22, was developed two serum cohorts consisting patients various solid tumors (n = 220) healthy subjects 33)...
As an increasing number of drugs are approved for targeted cancer therapy, comprehensive genomic profiling patients is frequently conducted to identify potentially relevant genetic variants. Different sequencing technologies used this purpose; gene panels cover a selected set biomarker genes and hotspot regions, while whole genome (WGS) delivers genome-wide data. This comparison study aimed at evaluating whether one method performs superiorly the other regarding detection targetable To...
We developed the supportive application with integrated patient-reported outcomes questionaries. This study tested application' feasibility in patients advanced pancreatic or lung cancer. In we included cancer of performance status 0-2 receiving 1st line systemic therapy. Patient-reported outcomes, adapted from National Cancer Institute, and three self-reflecting questions were sent to weekly. The predefined threshold severity determined initiating extraordinary healthcare professional'...
PURPOSE This randomized phase-II trial (ClinicalTrials.gov identifier: NCT02767557 ) compared efficacy of gemcitabine/nab-paclitaxel (Gem/Nab) with or without the anti–interleukin-6 (IL-6) receptor antibody tocilizumab (Toc) for advanced pancreatic cancer (PC). METHODS A safety cohort received Gem 1,000 mg/m 2 and Nab 125 on days 1, 8, 15, Toc 8 mg/kg day 1 each 28-day cycle. Participants modified Glasgow prognostic scores were randomly assigned 1:1 to receive Gem/Nab/Toc Gem/Nab. The...
Abstract The extracellular matrix (ECM) protein Beta-Ig H3 (βigH3, also known as transforming growth factor β induced (TGFBI)) is related to poor prognosis in patients with pancreatic ductal adenocarcinoma (PDAC). Proteolytic cleavage of βigH3 has been shown result release the N-terminal fragment covering amino acid 1 137, but whether degradation associated yet be determined. In this study we developed an ELISA targeting a collagenase generated (cβigH3) human serum use biomarker reflecting...